Delving into the Latest Updates on SL Bigen Co. Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Neoplasms

Cardiovascular Diseases

Stem cell therapy

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	4
Neoplasms	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Stem cell therapy	6
Fusion protein	1

Scheggia et al.¹ have established a behavioral paradigm to explore preferences for ′altruistic′ or ′selfish′ choice behavior in mice.The results suggest that altruistic behavior develops through reinforcement learning driven by social rewards, which is controlled by interactions between the basolateral amygdala and prelimbic cortex.

100 Deals associated with SL Bigen Co. Ltd.

Login to view more data

100 Translational Medicine associated with SL Bigen Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

2

IND Application

Phase 1 Clinical

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BM1021	Hypoxia-Ischemia, Brain More	Phase 1
BM1022	Brain Injuries, Traumatic More	Phase 1
BM2051	Glioblastoma Multiforme More	IND Application
BM2052	Neoplasms More	IND Application
BM2053	Solid tumor More	Preclinical